Abbott Laboratories (NYSE:ABT) Now Covered by Barclays

Key Points

• Barclays initiated coverage of Abbott Laboratories with an “overweight” rating and a $120 price target, implying 22.27% upside from the prior close.
• Analyst sentiment is broadly positive: Abbott has a consensus “Moderate Buy” rating and an average price target of $118.88, supported by multiple recent target increases and upgrades.
• Abbott recently beat quarterly earnings and revenue estimates, reporting $1.31 in EPS and $12.59 billion in revenue, while institutional investors own 75.18% of the company’s stock.

Investment analysts at Barclays started coverage on shares of Abbott Laboratories (NYSE:ABT - Get Free Report) in a research report issued to clients and investors on Wednesday, Benzinga reports. The brokerage set an "overweight" rating and a $120.00 price target on the healthcare product maker's stock. Barclays's target price suggests a potential upside of 22.27% from the company's previous close.

A number of other research analysts also recently commented on ABT. Piper Sandler reaffirmed an "overweight" rating and set a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. BTIG Research lifted their price objective on Abbott Laboratories from $131.00 to $134.00 and gave the company a "buy" rating in a research note on Friday, July 17th. Robert W. Baird started coverage on shares of Abbott Laboratories in a report on Wednesday, July 1st. They issued an "outperform" rating and a $121.00 price target on the stock. Weiss Ratings upgraded Abbott Laboratories from a "hold (c-)" rating to a "hold (c)" rating in a report on Friday, September 18th. Finally, Rothschild & Co Redburn raised Abbott Laboratories from a "neutral" rating to a "buy" rating and upped their target price for the stock from $119.00 to $127.00 in a research report on Friday, October 2nd. Three analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, Abbott Laboratories currently has a consensus rating of "Moderate Buy" and an average price target of $118.88.

Abbott Laboratories Stock Performance

Abbott Laboratories stock opened at $98.14 on Wednesday. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $135.13. The company has a market capitalization of $169.82 billion, a price-to-earnings ratio of 31.76, a PEG ratio of 1.86 and a beta of 0.59. The stock has a fifty day moving average of $106.71 and a two-hundred day moving average of $98.45. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating analysts' consensus estimates of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The business had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. During the same quarter last year, the company earned $1.26 earnings per share. The business's revenue for the quarter was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ABT. Cornerstone Financial Management LLC acquired a new stake in Abbott Laboratories during the fourth quarter valued at approximately $25,000. Purpose Unlimited Inc. acquired a new stake in shares of Abbott Laboratories during the 4th quarter worth approximately $25,000. Portfolio Resources Advisor Group Inc. bought a new stake in shares of Abbott Laboratories in the 4th quarter worth approximately $26,000. Abound Financial LLC bought a new stake in Abbott Laboratories in the fourth quarter valued at $26,000. Finally, Prudent Man Investment Management Inc. acquired a new position in shares of Abbott Laboratories during the fourth quarter valued at $33,000. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Company Profile

Abbott Laboratories NYSE: ABT is a diversified healthcare company that develops, manufactures and sells medical devices, diagnostic products, nutritional products and branded generic pharmaceuticals. Founded in 1888 by Wallace C. Abbott, the company serves healthcare providers, institutions, retailers and consumers worldwide.

Abbott's medical device portfolio includes cardiovascular products, such as coronary stents, structural heart systems and heart failure devices, as well as diabetes-care technologies, including the FreeStyle Libre continuous glucose monitoring system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.